CoChat

Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial

Open access

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Aims: Aspirin is widely used in cardiovascular disease prevention but is also associated with an increased risk of bleeding. The net effect of aspirin on dementia and cognitive impairment is uncertain. Methods and results: In the ASCEND trial, 15 480 people from the UK with diabetes and no history of cardiovascular disease were randomized to aspirin 100 mg daily or matching placebo for a mean of 7.4 years. The 15 427 ASCEND participants with no recorded dementia prior to baseline were included in this cognitive study with a primary pre-specified outcome of ‘broad dementia’, comprising dementia, cognitive impairment, or confusion. This was ascertained through participant, carer, or general practitioner report or hospital admission diagnosis, by 31 March 2019 (∼2 years beyond the scheduled treatment period). The broad dementia outcome occurred in a similar percentage of participants in the aspirin group and placebo group: 548 participants (7.1%) vs. 598 (7.8%), rate ratio 0.91 [95% confidence interval (CI), 0.81–1.02]. Thus, the CI excluded proportional hazards of >2% and proportional benefits of >19%. Conclusion: Aspirin does not have a large proportional effect on the risk of dementia. Trials or meta-analyses with larger total numbers of incident dementia cases to increase statistical power are needed to assess whether any modest proportional 10–15% benefits of 5–7 years of aspirin use on dementia exist. Clinical Trial Registration: Current Controlled Trials number, ISRCTN60635500; ClinicalTrials.gov number: NCT00135226.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehac179

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Structured Graphical Abstract The effect of aspirin on dementia in the ASCEND trial: Study design and summary results.
Structured Graphical Abstract The effect of aspirin on dementia in the ASCEND trial: Study design and summary results.CC BY · PubMed Central
Figure 1 Study profile. aPer cent of those not known to have died.
Figure 1 Study profile. aPer cent of those not known to have died.CC BY · PubMed Central
Figure 2 Effect of randomization to aspirin on dementia and cognitive function. Box sizes for the rate ratios are proportional to the amount of statistical information. aFifty-three individuals (26 on aspirin, 27 on placebo) are censored due to the broad dementia outcome before randomization. bCognitive z-score difference is adjusted for age at test and sex. The axis reversed to maintain the direction of ‘favours aspirin’ to the left.
Figure 2 Effect of randomization to aspirin on dementia and cognitive function. Box sizes for the rate ratios are proportional to the amount of statistical information. aFifty-three individuals (26 on aspirin, 27 on placebo) are censored due to the broad dementia outcome before randomization. bCognitive z-score difference is adjusted for age at test and sex. The axis reversed to maintain the direction of ‘favours aspirin’ to the left.CC BY · PubMed Central
Figure 3 Association of the incidence of vascular and bleed events with dementia. NEdem, number of participants with the non-fatal incident event and, subsequently, the broad dementia outcome; NE, total number of patients with the non-fatal incident event. aAdjusted for age, sex, randomized allocation, number of hospitalizations, incidence of the other non-fatal incident events, prior disease, and baseline predictors of dementia selected by backwards selection with psel = 0.2. bNon-disabling events (analyses are censored at disabling stroke or intracranial bleed). Intracranial bleed includes haemorrhagic stroke. cRate ratios associated with having the combined events tend to be higher than those with individual types because, for people with more than one type of event, they encompass the risks associated with each of the types of event.
Figure 3 Association of the incidence of vascular and bleed events with dementia. NEdem, number of participants with the non-fatal incident event and, subsequently, the broad dementia outcome; NE, total number of patients with the non-fatal incident event. aAdjusted for age, sex, randomized allocation, number of hospitalizations, incidence of the other non-fatal incident events, prior disease, and baseline predictors of dementia selected by backwards selection with psel = 0.2. bNon-disabling events (analyses are censored at disabling stroke or intracranial bleed). Intracranial bleed includes haemorrhagic stroke. cRate ratios associated with having the combined events tend to be higher than those with individual types because, for people with more than one type of event, they encompass the risks associated with each of the types of event.CC BY · PubMed Central
Figure 4 Effect of randomization to aspirin on dementia in a meta-analysis of three trials. Box sizes for the rate ratios are proportional to the amount of statistical information. aASPREE trial7: a randomized placebo-controlled trial of 100 mg daily aspirin in 19 114 healthy elderly individuals with a median follow-up of 4.7 years. The secondary endpoint of dementia is used. bJPAD trial8: a randomized open-label trial of 80–100 mg daily aspirin in 2536 patients with diabetes with a median follow-up of 11.4 years. cThe ASCEND broad dementia outcome is used. dFixed-effects meta-analysis of ASPREE, JPAD, and ASCEND.
Figure 4 Effect of randomization to aspirin on dementia in a meta-analysis of three trials. Box sizes for the rate ratios are proportional to the amount of statistical information. aASPREE trial7: a randomized placebo-controlled trial of 100 mg daily aspirin in 19 114 healthy elderly individuals with a median follow-up of 4.7 years. The secondary endpoint of dementia is used. bJPAD trial8: a randomized open-label trial of 80–100 mg daily aspirin in 2536 patients with diabetes with a median follow-up of 11.4 years. cThe ASCEND broad dementia outcome is used. dFixed-effects meta-analysis of ASPREE, JPAD, and ASCEND.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 41

Metadata

Authors
Parish, S., Mafham, M., Offer, A., Barton, J., Wallendszus, K., Stevens, W., Buck, G., Haynes, R., Collins, R., Bowman, L., & Armitage, J.
Affiliations
University of Oxford (GB)
Corresponding author
Parish, Sarah
Venue
European Heart Journal
Published
2022-04-08
Volume
43
Issue
21
Pages
2010-2019
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W4226446021
Cited by
40
References
27
Citations by year
2026: 3 · 2025: 7 · 2024: 11 · 2023: 15 · 2022: 4
FWCI
6.44
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • British Heart Foundation (SP/03/002, SP/08/010/25939, SP/14/3/31114, PG/05/013/18296)
  • Alzheimers Research UK
  • UK Medical Research Council (MC-UU_00017/3, MC-UU_00017/5)
  • Cancer Research UK
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
aspirin, dementia, cognitive impairment, diabetes mellitus, ASCEND trial, cardiovascular disease prevention, bleeding risk, dementia risk
MeSH terms
Aspirin, Cognition, Dementia, Diabetes Mellitus, Humans, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehac179
The paper
Parish, S., Mafham, M., Offer, A., Barton, J., Wallendszus, K., Stevens, W., Buck, G., Haynes, R., Collins, R., Bowman, L., & Armitage, J. (2022). Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehac179

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.